KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Neogenomics (NEO) Equity Average (2016 - 2025)

Historic Equity Average for Neogenomics (NEO) over the last 16 years, with Q3 2025 value amounting to $846.2 million.

  • Neogenomics' Equity Average fell 722.35% to $846.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $846.2 million, marking a year-over-year decrease of 722.35%. This contributed to the annual value of $921.9 million for FY2024, which is 493.33% down from last year.
  • According to the latest figures from Q3 2025, Neogenomics' Equity Average is $846.2 million, which was down 722.35% from $871.2 million recorded in Q2 2025.
  • Neogenomics' Equity Average's 5-year high stood at $1.1 billion during Q3 2021, with a 5-year trough of $769.0 million in Q1 2021.
  • In the last 5 years, Neogenomics' Equity Average had a median value of $951.8 million in 2023 and averaged $965.5 million.
  • As far as peak fluctuations go, Neogenomics' Equity Average soared by 7307.41% in 2021, and later plummeted by 1044.35% in 2022.
  • Over the past 5 years, Neogenomics' Equity Average (Quarter) stood at $1.1 billion in 2021, then decreased by 10.44% to $1.0 billion in 2022, then fell by 6.07% to $944.5 million in 2023, then dropped by 4.15% to $905.3 million in 2024, then fell by 6.53% to $846.2 million in 2025.
  • Its last three reported values are $846.2 million in Q3 2025, $871.2 million for Q2 2025, and $895.3 million during Q1 2025.